Research and Development of Cannabinoid Pharmaceuticals in Accordance with United States Food and Drug Administration (FDA) Regulatory Pathways.
Nexien BioPharma operates in strict compliance with United States Drug Enforcement Administration (DEA) licensed pharmaceutical clinical research organizations (CRO's), contract manufacturing partners (CDMO's), and prestigious academic research institutions.
Developing, licensing and commercializing cannabinoid based medications for specific medical conditions and disorders. Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries.
Our intent is that any medications we develop will be physician prescribed.
The development and licensing of proprietary delivery systems for cannabinoid medications. In addition to the Company’s precision parenteral formulations, the Company’s advanced tablet technology provides for the accurate oral and sublingual dosing of cannabinoid API’s with our without adjunct API’s for both human (PerfectDose™) and veterinary applications (Triit™).
Investments in companies, and the acquisition of technologies, or medications, focused on cannabinoid-based research, through Special Purpose Vehicles (SPV) controlled by Nexien BioPharma Inc.
Chief Executive Officer and Chairman, Nexien BioPharma Inc
Chief Operating Officer, Nexien BioPharma Inc
Chief Financial Officer, Nexien BioPharma Inc
Copyright 2024 Nexien BioPharma Inc | All Rights Reserved